Cellerant adds two new management components
This article was originally published in Scrip
Executive Summary
Cellerant Therapeutics, a biotechnology company which specialises in therapies for blood disorders, has appointed Dr Margaret Dillon as vice president of regulatory affairs and Dr Robert Tressler as vice president of research and development. Dr Dillon comes to Cellerant with 19 years of experience in pharmaceutical regulatory affairs, most recently with CV Therapeutics (now Gilead Sciences). Dr Tressler brings to the table 20 years of industry experience in oncology, cardiovascular and immunological indications. Most recently, he served as executive director of research for Geron.